Thrombosis Prevention and Anticoagulation Management in the Pediatric Patient with Congenital Heart Disease

被引:16
作者
Abdelghani, Eman [1 ,3 ]
Cua, Clifford L. [2 ,3 ]
Giver, Jean [1 ,3 ]
Rodriguez, Vilmarie [1 ,3 ]
机构
[1] Nationwide Childrens Hosp, Div Pediat Hematol Oncol, Columbus, OH USA
[2] Nationwide Childrens Hosp, Heart Ctr, 700 Childrens Dr, Columbus, OH 43205 USA
[3] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA
关键词
Anticoagulation; Thrombosis; Congenital heart disease; Warfarin; Heparin; Aspirin; HEPARIN-INDUCED THROMBOCYTOPENIA; COAGULATION-FACTOR ABNORMALITIES; MOLECULAR-WEIGHT HEPARIN; CARDIAC-CATHETERIZATION; VENOUS THROMBOEMBOLISM; VALVE THROMBOSIS; SCIENTIFIC STATEMENT; CONSENSUS STATEMENT; CANADIAN REGISTRY; LIVER-FUNCTION;
D O I
10.1007/s40119-021-00228-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Thrombosis is one of the most frequent complications affecting children with congenital heart disease (CHD). Palliative and reparative cardiac surgeries are some of the main players contributing to the thrombosis risk in this patient population. Additional risk factors related to the CHD itself (e.g., cardiac dysfunction, arrhythmias, and polycythemia in cyanotic cardiac disorders) can contribute to thrombogenicity alone or combined with other factors. Thrombotic complications have been recognized as a significant cause of morbidity and mortality in this patient population. Here, we provide an overview of the pathophysiology and risk factors for thrombosis as well as the indications for and use of different anticoagulation, antiplatelet, and thrombolytic agents. In addition, we describe some of most common thrombotic complications and their management in the pediatric CHD population.
引用
收藏
页码:325 / 348
页数:24
相关论文
共 124 条
[1]  
Al Jubair KA, 1998, CARDIOL YOUNG, V8, P486
[2]   Assessment of Late Thromboembolic Complications Post-Fontan Procedure in Relation to Different Antithrombotic Regimens: 30-Years' Follow-up Experience [J].
Al-Jazairi, Abdulrazaq S. ;
Al Alshaykh, Hana A. ;
Di Salvo, Giovanni ;
De Vol, Edward B. ;
Alhalees, Zohair Y. .
ANNALS OF PHARMACOTHERAPY, 2019, 53 (08) :786-793
[3]   Thrombosis in children with cardiac pathology: analysis of acquired and inherited risk factors [J].
Alioglu, Bulent ;
Avci, Zekai ;
Tokel, Kursat ;
Atac, F. Belgin ;
Ozbek, Namik .
BLOOD COAGULATION & FIBRINOLYSIS, 2008, 19 (04) :294-304
[4]  
ANDREW M, 1994, THROMB HAEMOSTASIS, V71, P265
[5]   VENOUS THROMBOEMBOLIC COMPLICATIONS (VTE) IN CHILDREN - FIRST ANALYSES OF THE CANADIAN REGISTRY OF VTE [J].
ANDREW, M ;
DAVID, M ;
ADAMS, M ;
ALI, K ;
ANDERSON, R ;
BARNARD, D ;
BERNSTEIN, M ;
BRISSON, L ;
CAIRNEY, B ;
DESAI, D ;
GRANT, R ;
ISRAELS, S ;
JARDINE, L ;
LUKE, B ;
MASSICOTTE, P ;
SILVA, M .
BLOOD, 1994, 83 (05) :1251-1257
[6]  
Andrew M., 2000, Thromboembolic Complications during Infancy and Childhood
[7]   Pharmacology and management of the vitamin K antagonists [J].
Ansell, Jack ;
Hirsh, Jack ;
Hylek, Elaine ;
Jacobson, Alan ;
Crowther, Mark ;
Palareti, Gualtiero .
CHEST, 2008, 133 (06) :160S-198S
[8]   Evaluation of enoxaparin dosing requirements in infants and children Better dosing to achieve therapeutic levels [J].
Bauman, Mary E. ;
Belletrutti, Mark J. ;
Bajzar, Laszlo ;
Black, Karina L. ;
Kuhle, Stefan ;
Bauman, Michelle L. ;
Massicotte, M. Patricia .
THROMBOSIS AND HAEMOSTASIS, 2009, 101 (01) :86-92
[9]   The ESC Clinical Practice Guidelines for the Management of Adult Congenital Heart Disease 2020 [J].
Baumgartner, Helmut ;
De Backer, Julie .
EUROPEAN HEART JOURNAL, 2020, 41 (43) :4153-4154
[10]   Outcome of cardiac thrombi in infants [J].
Bendaly, Edgard A. ;
Batra, Anjan S. ;
Ebenroth, Eric S. ;
Hurwitz, Roger A. .
PEDIATRIC CARDIOLOGY, 2008, 29 (01) :95-101